2025-04-04 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**0. Executive Summary:**

Eli Lilly and Co. (LLY) is a leading pharmaceutical company.  The analysis below reveals significantly higher cumulative returns compared to the S&P 500 (VOO), exhibiting strong momentum despite recent price drops.  While short-term indicators suggest caution, long-term prospects remain positive based on strong financial performance and high expected returns.

**1. Performance Comparison:**

* **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products.

* **Cumulative Returns:**
    * LLY: 338.58%
    * VOO (S&P 500): 85.44%
    * Return Difference: 253.14%
    * Relative Divergence: 65.5% (This indicates LLY's performance is in the upper 65.5th percentile of its historical range relative to the S&P 500)

* **Alpha and Beta Analysis:** The provided data shows consistently positive alpha values across multiple years, indicating LLY outperformed the market benchmark. Beta values suggest a higher-than-average market sensitivity (higher than 1), except for 2016-2018.  Market capitalization (Cap(B)) has steadily increased, reflecting the company's growth.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 8.3% | -7.0% | 0.1 | 67.7 |
| 2016-2018  | 47.0% | 8.3% | 41.0% | -0.0 | 95.1 |
| 2017-2019  | 59.0% | 9.8% | 40.0% | 0.3 | 110.4 |
| 2018-2020  | 70.0% | 13.5% | 36.0% | 0.2 | 144.7 |
| 2019-2021  | 118.0% | 13.5% | 45.0% | 0.1 | 240.3 |
| 2020-2022  | 128.0% | 48.4% | 116.0% | 0.1 | 322.6 |
| 2021-2023  | 182.0% | 51.4% | 164.0% | 0.3 | 519.2 |
| 2022-2024  | 206.0% | 55.2% | 183.0% | 0.3 | 692.0 |
| 2023-2025  | 162.0% | 81.7% | 125.0% | 0.2 | 708.6 |


**2. Recent Price Movement:**

* Closing Price: $789.09
* Previous Close: $818.22
* Change: -$29.13 (significant drop)
* 5-Day Moving Average: $812.19
* 20-Day Moving Average: $827.57
* 60-Day Moving Average: $832.95

The stock price is currently below all three moving averages, indicating a bearish short-term trend.  The significant price drop from the previous close warrants further investigation into potential catalysts for this decline.


**3. Technical Indicators:**

* Market Risk Indicator (MRI): 0.432 (Medium Risk)
* RSI: 43.08 (Approaching oversold territory, but not yet definitively so)
* PPO: -0.54 (Negative, indicating bearish momentum)
* 20-Day Relative Divergence Change: -0.2 (Short-term downward trend)
* Expected Return: 110.9% (Significant potential long-term outperformance relative to the S&P 500)

The combination of a negative PPO, declining relative divergence, and the recent price drop suggests a bearish short-term outlook. However, the high expected return indicates strong potential for long-term growth.  The drop from previous close suggests potential short-term volatility.


**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue       |
|------------|---------|---------------|
| 2024-10-30 | $1.08   | $11.44 B      |
| 2024-08-08 | $3.29   | $11.30 B      |
| 2024-04-30 | $2.49   | $8.77 B       |
| 2023-11-02 | -$0.06  | $9.50 B       |
| 2024-10-30 | -$0.06  | $9.50 B       |

There appears to be a duplicate entry for October 30th, 2024.  Excluding the duplicate, revenue has generally remained stable, while EPS has fluctuated.  The negative EPS in November 2023 and the duplicated entry requires further investigation.  A more detailed analysis would require access to additional financial statements.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $13.53B | 82.24%       |
| 2024-09-30 | $11.44B | 81.02%       |
| 2024-06-30 | $11.30B | 80.80%       |
| 2024-03-31 | $8.77B  | 80.91%       |
| 2023-12-31 | $9.35B  | 80.88%       |

Revenue shows a clear upward trend, with consistently high profit margins.


**Capital and Profitability:**

| Quarter | Equity   | ROE      |
|---------|----------|----------|
| 2024-12-31 | $14.19B | 31.07%   |
| 2024-09-30 | $14.24B | 6.81%    |
| 2024-06-30 | $13.56B | 21.88%   |
| 2024-03-31 | $12.81B | 17.51%   |
| 2023-12-31 | $10.77B | 20.33%   |

Equity has increased, but ROE shows significant fluctuation, needing further investigation into the causes of the variations between quarters.


**6. Overall Conclusion:**

LLY has demonstrated exceptionally strong long-term performance significantly outpacing the S&P 500.  The high expected return suggests continued outperformance potential. However, recent price action and technical indicators signal a short-term bearish trend.  Further investigation is needed into the recent price drop and the inconsistencies in the earnings and financial data.  Long-term investors should consider the high potential returns against the risk of short-term volatility.  A more thorough analysis including a deeper dive into the recent earnings reports and news affecting the company is recommended before making investment decisions.
